CompletedNCT01933919
Fluvoxamine Compared With Placebo for OCD in Young People
About this title
A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With Obsessive Compulsive Disorder
Read the official source — NCT01933919Medication studyAges 6–18
Understand this study
Who was this study for?
This study was for people with OCD. Listed age limits: 6 years to 18 years. Other eligibility criteria applied.
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: August 14, 2013
- Recruitment status
- Completed
- Enrollment listed in the registry
- 38
- Sponsor
- AbbVie
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Not clearly listed
- Age range
- From 6 Years to 18 Years
- Official registry ID
- NCT01933919
- Official title
Show the full official title
A Phase 3 Study of SME3110 (Fluvoxamine Maleate) in Pediatric/Adolescent Subjects With Obsessive Compulsive Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Locations not listed
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is AbbVie.
Did this study involve medication?
Yes. The study involved medication, including Fluvoxamine maleate and Placebo.
Who was this study for?
This study was for people with OCD. Listed age limits: 6 years to 18 years. Other eligibility criteria applied.
